- Home
- FURY vs CVM Comparison
FURY vs CVM Comparison
Compare FURY & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- CVM
- Stock Information
- Founded
- FURY 2008
- CVM 1983
- Country
- FURY Canada
- CVM United States
- Employees
- FURY N/A
- CVM N/A
- Industry
- FURY Precious Metals
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FURY Basic Materials
- CVM Health Care
- Exchange
- FURY Nasdaq
- CVM Nasdaq
- Market Cap
- FURY 59.5M
- CVM 68.9M
- IPO Year
- FURY N/A
- CVM 1987
- Fundamental
- Price
- FURY $0.41
- CVM $0.56
- Analyst Decision
- FURY Strong Buy
- CVM
- Analyst Count
- FURY 1
- CVM 0
- Target Price
- FURY $2.00
- CVM N/A
- AVG Volume (30 Days)
- FURY 181.3K
- CVM 450.5K
- Earning Date
- FURY 11-12-2024
- CVM 12-19-2024
- Dividend Yield
- FURY N/A
- CVM N/A
- EPS Growth
- FURY N/A
- CVM N/A
- EPS
- FURY N/A
- CVM N/A
- Revenue
- FURY N/A
- CVM N/A
- Revenue This Year
- FURY N/A
- CVM N/A
- Revenue Next Year
- FURY N/A
- CVM $3,412.81
- P/E Ratio
- FURY N/A
- CVM N/A
- Revenue Growth
- FURY N/A
- CVM N/A
- 52 Week Low
- FURY $0.32
- CVM $0.54
- 52 Week High
- FURY $0.59
- CVM $3.23
- Technical
- Relative Strength Index (RSI)
- FURY 37.64
- CVM 16.48
- Support Level
- FURY $0.39
- CVM $0.68
- Resistance Level
- FURY $0.48
- CVM $0.92
- Average True Range (ATR)
- FURY 0.04
- CVM 0.06
- MACD
- FURY -0.01
- CVM -0.02
- Stochastic Oscillator
- FURY 10.28
- CVM 0.06
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.